Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rigel ( (RIGL) ) has shared an announcement.
On April 16, 2026, Rigel Pharmaceuticals received notice that Eli Lilly is terminating their 2021 license and collaboration agreement, which will become effective June 15, 2026. The deal had granted Lilly exclusive global rights to develop and commercialize ocadusertib and other RIPK1 inhibitors for non-CNS and CNS diseases, along with joint development activities and potential milestone and royalty payments to Rigel.
Upon termination, Lilly’s rights to the licensed compounds will cease, subject to transition provisions, and Rigel expects to regain full rights to ocadusertib and related programs. Following this move and the earlier November 2025 termination of the CNS program, Rigel does not expect future milestones or royalties from the agreement and is currently evaluating the impact on its business and development strategy.
The most recent analyst rating on (RIGL) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.
Spark’s Take on RIGL Stock
According to Spark, TipRanks’ AI Analyst, RIGL is a Outperform.
The score is supported most by improving fundamentals (profitability, revenue growth, stronger cash generation and balance sheet) and very low P/E valuation. Offsetting this are weak technicals (downtrend and negative momentum signals) and earnings-quality/execution risks highlighted on the earnings call, including tax-benefit-driven GAAP income and potential non-recurring growth tailwinds.
To see Spark’s full report on RIGL stock, click here.
More about Rigel
Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapies. Its pipeline includes investigational kinase inhibitors such as ocadusertib, a potent and selective RIPK1 inhibitor being developed for the treatment of various immune-inflammatory and related non-CNS and CNS diseases.
Average Trading Volume: 347,990
Technical Sentiment Signal: Buy
Current Market Cap: $592.2M
For detailed information about RIGL stock, go to TipRanks’ Stock Analysis page.